NV1020
AXP000075.1 · Oncolytic virus
- Platform
- HSV-1/HSV-2 recombinant (R7020 backbone)
- Originator
- University of Chicago (Bernard Roizman)
- Sponsor
- MediGene
Names
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- R7020 (HSV-1 F background with HSV-2 sequences)
- Replication
- conditionally replicating
- Modifications
- one copy each of RL1 (gamma34.5), ICP0 and ICP4 deleted; UL56 deleted; internal repeat replaced by an HSV-2 US fragment; thymidine kinase placed under the ICP4 promoter
- Route
- intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2623
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00149396 | Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver | Completed | Phase 1/2 | 2004-07 | 2008-10 | 32 | Colorectal Cancer; Liver Neoplasms |
| NCT00012155 | Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver | Completed | Phase 1 | 2000-10 | 2002-11 | Colorectal Cancer; Metastatic Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 21895536 | Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. | Human gene therapy | 2012 | cited by trial NCT00149396 |
| PMID 20486770 | Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. | Human gene therapy | 2010 | name in title: NV1020 |
| PMID 19018254 | A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in abstract: NV1020 |
| PMID 17107303 | Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. | Human gene therapy | 2006 | name in title: NV1020 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 29896663 | Oncolytic Virotherapy by HSV. | Advances in experimental medicine and biology | 2018 | name in abstract: NV1020 |
| PMID 30563466 | Oncolytic herpes simplex virus and immunotherapy. | BMC immunology | 2018 | name in abstract: NV1020 |
| PMID 26132411 | Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia. | PloS one | 2015 | name in title: R7020 |
| PMID 21567107 | Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. | Oncology reports | 2011 | name in abstract: NV1020 |
| PMID 19526622 | Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. | The British journal of surgery | 2009 | name in abstract: NV1020 |
| PMID 18518998 | Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. | Virology journal | 2008 | name in title: NV1020 |
| PMID 18549346 | Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. | Expert opinion on investigational drugs | 2008 | name in title: NV1020 |
| PMID 17536976 | Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. | Human gene therapy | 2007 | name in title: NV1020 |
| PMID 16475242 | Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. | The journal of gene medicine | 2006 | name in abstract: NV1020 |
| PMID 16574492 | Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in abstract: NV1020 |
| PMID 16675589 | Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in abstract: NV1020 |
| PMID 17117895 | Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. | Human gene therapy | 2006 | name in title: NV1020 |
| PMID 15665822 | Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. | Cancer gene therapy | 2005 | name in abstract: NV1020 |
| PMID 15696053 | Modulation of vascular remodeling induced by a brief intraluminal exposure to the recombinant R7020 strain of Herpes simplex-1. | Journal of vascular surgery | 2005 | name in title: R7020 |
| PMID 15735042 | Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. | Cancer research | 2005 | name in abstract: NV1020 |
| PMID 16121703 | Technology evaluation: NV-1020, MediGene. | Current opinion in molecular therapeutics | 2005 | name in title: NV1020 |
| PMID 15185293 | Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. | Hepatology (Baltimore, Md.) | 2004 | name in abstract: NV1020 |
| PMID 11850725 | The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. | Gene therapy | 2002 | name in title: R7020 |
| PMID 12091817 | Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. | The Journal of thoracic and cardiovascular surgery | 2002 | name in title: NV1020 |
| PMID 12218591 | Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. | Journal of pediatric hematology/oncology | 2002 | name in abstract: NV1020 |
| PMID 12242723 | Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. | The Prostate | 2002 | name in abstract: NV1020 |
| PMID 12386832 | Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. | Cancer gene therapy | 2002 | name in title: NV1020 |
| PMID 12522436 | Oncolytic herpes simplex virus vectors for cancer virotherapy. | Cancer gene therapy | 2002 | name in abstract: NV1020 |
| PMID 11344122 | Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 2001 | name in title: NV1020 |
| PMID 11442249 | Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. | Journal of the American College of Surgeons | 2001 | name in abstract: NV1020 |
| PMID 11119418 | Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. | Human gene therapy | 2000 | name in abstract: NV1020 |
| PMID 11307092 | Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract | 2000 | name in abstract: NV1020 |
| PMID 2165104 | In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). | The Journal of infectious diseases | 1990 | name in title: R7020 |
| PMID 2842408 | In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. | The Journal of infectious diseases | 1988 | name in title: R7020 |
Unconfirmed matches (3)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 25119379 | Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. | Gene therapy | 2014 | name in abstract: R7020 |
| PMID 10232586 | Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. | Cancer research | 1999 | name in abstract: R7020 |
| PMID 1780614 | Genetically engineered attenuated herpes simplex viruses. | Reviews of infectious diseases | 1991 | name in abstract: R7020 |
NIH grants
No confirmed grants yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA083066 | IMAGING TRANSGENE EXPRESSION IN GENE THERAPY PROTOCOLS | SLOAN-KETTERING INST CAN RESEARCH | BLASBERG, RONALD G | 2002–2004 | name in abstract: R7020 |
Notes
Originally R7020, built as a live attenuated HSV vaccine candidate, later developed as an oncolytic for colorectal liver metastases by NeuroVir and MediGene (phase I/II by hepatic arterial infusion). Discontinued; the asset later passed to Catherex, acquired by Amgen in 2015 (deal not re-verified here).
How to cite
NV1020 (AXP000075.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000075.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.